

Niraparib – Licensing deal with Merck



LEERINK SWANN

- \$7MM upfront payment to Merck
- Up to \$57MM in milestones for the 1st indication
- Up to \$29.5MM in milestones for each successive indication
- Up to \$87.5MM in one-time sales milestones
- Tiered royalties to Merck in low teens
- Effective until the later of
 - Expiration of the last patent licensed
 - The 10th year after the first commercial sale
- Deal in June 2012